Global Human Albumin Market 2016-2020 - New Market Study Published
Albumin-based therapies such as Idelvion (CSL654 rIX-FP) by CSL Behring received marketing approval from the US FDA in March 2016 and from the EMA in May 2016. Apart from these, Albutropin (TV-1106) by Teva Pharmaceuticals, Ampion by Ampio Pharmaceuticals, and Albutein by Grifols (for Alzheimer's disease) are expected to enter the market during the forecast period.
View full press release